Intercept to go back to FDA with its NASH treatment application https://ift.tt/mjGQWty

The FDA declined to approve the therapy in 2020, saying the predicted benefit remains uncertain and does not sufficiently outweigh the potential risks. At the time, the FDA recommended Intercept submit additional data from the late-stage study.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/NvP8pZd
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.